|
gptkbp:instanceOf
|
gptkb:drug
PARP inhibitor
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2014
|
|
gptkbp:ATCCode
|
gptkb:L01XX43
|
|
gptkbp:brand
|
gptkb:Lynparza
|
|
gptkbp:CASNumber
|
763113-22-0
|
|
gptkbp:chemicalFormula
|
C24H23FN4O3
|
|
gptkbp:contraindication
|
pregnancy
severe hepatic impairment
hypersensitivity to olaparib
|
|
gptkbp:developedBy
|
gptkb:AstraZeneca
gptkb:Merck_&_Co.
|
|
gptkbp:eliminationHalfLife
|
11-12 hours
|
|
gptkbp:form
|
gptkb:tablet
capsule
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
olaparib
|
|
gptkbp:indication
|
BRCA-mutated cancers
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits PARP enzymes
|
|
gptkbp:metabolism
|
gptkb:CYP3A4
|
|
gptkbp:pregnancyCategory
|
gptkb:D_(Australia)
D (US)
|
|
gptkbp:proteinBinding
|
82%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL521686
DB09074
23725625
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
vomiting
diarrhea
fatigue
headache
decreased appetite
dysgeusia
|
|
gptkbp:synonym
|
gptkb:AZD2281
gptkb:KU-0059436
|
|
gptkbp:target
|
gptkb:PARP1
gptkb:PARP2
gptkb:PARP3
|
|
gptkbp:UNII
|
7JY1SQI1TX
|
|
gptkbp:usedFor
|
gptkb:cancer
pancreatic cancer
prostate cancer
|
|
gptkbp:bfsParent
|
gptkb:Lynparza
|
|
gptkbp:bfsLayer
|
5
|